Our site may be slower due to heavy traffic from automated "bots" and AI crawlers. We're working to fix this.

Rebecca Shatsky

Photo of Rebecca Shatsky
Title(s)Clinical Professor, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Overview 

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial. Ann Surg Oncol. 2025 Aug 23. Van Hassel J, Dimitroff K, Yau C, Mukhtar R, Boughey JC, Ladores V, Howard-McNatt MM, Jaskowiak N, Perlmutter J, DeMichele A, Yee D, Hylton N, Symmans WF, Veer LV, Rugo H, Esserman LJ, Shatsky R, Isaacs C, Kuerer H, Wallace AM, Prionas N, Tseng J, Reyna CR, Taunk N, Kesmodel S, Lee MC, Fox J, Piltin MA, Tchou J, Arciero CA, Postlewait LM, Sauder C, Rao R. PMID: 40849380.
      View in: PubMed   Mentions:    Fields:    
    2. Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial. Ann Surg Oncol. 2025 Jul 24. Mukhtar RA, Dimitroff K, Yau C, Chien AJ, Connolly EP, Howard-McNatt M, Rao R, Ladores V, Golshan M, Sauder CA, Ahmed K, Lancaster R, Fox J, Gutnik L, Lee MC, Tchou J, Prionas N, Arciero CA, Reyna C, Kuerer H, Switalla K, Taunk N, Tuttle TM, Moran MS, Postlewait LM, Perlmutter J, DeMichele A, Yee D, Hylton N, Symmans WF, Rugo HS, Shatsky R, Isaacs C, Esserman LJ, Van't Veer L, Boughey JC. PMID: 40705266.
      View in: PubMed   Mentions:    Fields:    
    3. Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial. Ann Surg Oncol. 2025 Jul 23. Kaur M, Dimitroff K, Boughey JC, Esserman LJ, Yau C, Tchou J, Quirarte A, Lee MC, Howard-McNatt MM, Switalla K, Kuerer H, Sauder C, Postlewait LM, Arciero C, Rao R, Wallace A, Reyna C, Ahmed K, Gutnik L, Taunk N, Perlmutter J, DeMichele A, Yee D, Hylton NM, Symmans WF, Rugo HS, Shatsky RA, Isaacs C, Rudra S, Pohlmann P, Ewing C, Wong J, Alvarado M, Jaskowiak N, Prionas N, Golshan M, Piltin MA, Olopade OI, Mukhtar RA. PMID: 40699532.
      View in: PubMed   Mentions:    Fields:    
    4. Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial. JCO Precis Oncol. 2025 Jun; 9:e2400776. Wolf DM, Yau C, Campbell M, Glas A, Barcaru A, Mittempergher L, Kuilman M, Brown-Swigart L, Hirst G, Basu A, Magbanua M, Sayaman R, Huppert L, Delson A, I-SPY2 Investigators, Symmans WF, Borowsky A, Pohlmann P, Rugo H, Clark A, Yee D, DeMichele A, Perlmutter J, Petricoin EF, Chien J, Stringer-Reasor E, Shatsky R, Liu M, Han H, Soliman H, Isaacs C, Nanda R, Hylton N, Pusztai L, Esserman L, van 't Veer L. PMID: 40526879; PMCID: PMC12184982.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    5. Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer Symposium. Clin Breast Cancer. 2025 Aug; 25(6):e699-e706. Jhaveri K, Anders CK, Bardia A, Bhave M, Chien AJ, Krop I, Traina TA, Abdou Y, Basho R, Conlin AK, Esteva FJ, Fox KR, Gadi V, Kaufman PA, Litvak A, Ma CX, Mamounas EP, McArthur H, McCann K, Mitri Z, Shatsky R, Telli M, Torres MA, Kalinsky K. PMID: 40340127.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial. Ann Oncol. 2025 Feb; 36(2):172-184. Huppert LA, Wolf D, Yau C, Brown-Swigart L, Hirst GL, Isaacs C, Pusztai L, Pohlmann PR, DeMichele A, Shatsky R, Yee D, Thomas A, Nanda R, Perlmutter J, Heditsian D, Hylton N, Symmans F, Van't Veer LJ, Esserman L, Rugo HS. PMID: 39477071.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    7. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3737-3747. Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, Tsiatis B, Wallace AM, Chien AJ, Stringer-Reasor E, Boughey JC, Omene C, Rozenblit M, Kalinsky K, Elias AD, Vaklavas C, Beckwith H, Williams N, Arora M, Nangia C, Roussos Torres ET, Thomas B, Albain KS, Clark AS, Falkson C, Hershman DL, Isaacs C, Thomas A, Tseng J, Sanford A, Yeung K, Boles S, Chen YY, Huppert L, Jahan N, Parker C, Giridhar K, Howard FM, Blackwood MM, Sanft T, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Symmans WF, Price E, Heditsian D, LeStage B, Perlmutter J, Pohlmann P, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ. PMID: 39277672; PMCID: PMC12089997.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    8. Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3728-3736. Khoury K, Meisel JL, Yau C, Rugo HS, Nanda R, Davidian M, Tsiatis B, Chien AJ, Wallace AM, Arora M, Rozenblit M, Hershman DL, Zimmer A, Clark AS, Beckwith H, Elias AD, Stringer-Reasor E, Boughey JC, Nangia C, Vaklavas C, Omene C, Albain KS, Kalinsky KM, Isaacs C, Tseng J, Roussos Torres ET, Thomas B, Thomas A, Sanford A, Balassanian R, Ewing C, Yeung K, Sauder C, Sanft T, Pusztai L, Trivedi MS, Outhaythip A, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Fraser Symmans W, Price E, Beedle C, Perlmutter J, Pohlmann P, Shatsky RA, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ. PMID: 39277671; PMCID: PMC12044543.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    9. Systemic Therapy in Breast Cancer. Am Soc Clin Oncol Educ Book. 2024 Jun 01; 44(3):e432442. Corti C, Batra-Sharma H, Kelsten M, Shatsky RA, Garrido-Castro AC, Gradishar WJ. PMID: 39013124.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    10. Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer. Breast Cancer Res. 2024 Mar 13; 26(1):46. Shatsky RA, Batra-Sharma H, Helsten T, Schwab RB, Pittman EI, Pu M, Weihe E, Ghia EM, Rassenti LZ, Molinolo A, Cabrera B, Breitmeyer JB, Widhopf Ii GF, Messer K, Jamieson C, Kipps TJ, Parker BA. PMID: 38481291; PMCID: PMC10938766.
      View in: PubMed   Mentions: 1     Fields:    
    11. A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer. Breast Cancer Res. 2024 02 26; 26(1):32. Shatsky RA, Batra-Sharma H, Helsten T, Schwab RB, Pittman EI, Pu M, Weihe E, Ghia EM, Rassenti LZ, Molinolo A, Cabrera B, Breitmeyer JB, Widhopf GF, Messer K, Jamieson C, Kipps TJ, Parker BA. PMID: 38408999; PMCID: PMC10895766.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    12. Moving precision forward: extending next generation sequencing to operable disease in less common breast cancer subtypes. Ann Oncol. 2024 Jan; 35(1):7-9. Thomas A, Shatsky R, Kalinsky K. PMID: 37871698.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    13. Erratum: 53 The development of a multi-institutional prospective registry for patients with metastatic invasive lobular carcinoma: identifying new markers of disease progression - CORRIGENDUM. J Clin Transl Sci. 2023; 7(1):e202. Rothschild HT, Jo Chien A, Jankowitz RC, Magbanua MJ, Mouabbi JA, Shatsky RA, Levine J, Mukhtar RA. PMID: 37830005; PMCID: PMC10565189.
      View in: PubMed   Mentions: 1  
    14. Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial. Breast Cancer Res Treat. 2023 Jun; 199(2):281-291. Parker BA, Shatsky RA, Schwab RB, Wallace AM, I-SPY 2 Consortium, Wolf DM, Hirst GL, Brown-Swigart L, Esserman LJ, van 't Veer LJ, Ghia EM, Yau C, Kipps TJ. PMID: 37029329; PMCID: PMC10175386.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    15. Evaluating Cancer Pain Characteristics and Treatment Factors in the Emergency Department: A Retrospective Cohort Study. J Palliat Care. 2022 Oct; 37(4):486-493. Gupta R, Lin L, Resley V, Khan A, Li DR, Shatsky RA, Coyne CJ. PMID: 35979605; PMCID: PMC9465546.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    16. Procalcitonin as a Predictive Tool for Death and ICU Admission among Febrile Neutropenic Patients Visiting the Emergency Department. Medicina (Kaunas). 2022 Jul 23; 58(8). Coyne CJ, Castillo EM, Shatsky RA, Chan TC. PMID: 35893100; PMCID: PMC9329824.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    17. Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2022 09 20; 40(27):3205-3221. Henry NL, Somerfield MR, Dayao Z, Elias A, Kalinsky K, McShane LM, Moy B, Park BH, Shanahan KM, Sharma P, Shatsky R, Stringer-Reasor E, Telli M, Turner NC, DeMichele A. PMID: 35759724.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    18. 18F-FES PET/CT Improves the Detection of Intraorbital Metastases in Estrogen-Receptor-Positive Breast Cancer: Two Representative Cases and Review of the Literature. Tomography. 2022 04 07; 8(2):1060-1065. Bodapati S, Abraham P, Chen A, Guilbault D, McDonald M, Matro J, Shatsky R, Obrzut S. PMID: 35448720; PMCID: PMC9024434.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    19. Comparison of Early- and Late-Stage Breast and Colorectal Cancer Diagnoses During vs Before the COVID-19 Pandemic. JAMA Netw Open. 2022 02 01; 5(2):e2148581. Zhou JZ, Kane S, Ramsey C, Akhondzadeh M, Banerjee A, Shatsky R, Gold KA. PMID: 35166787; PMCID: PMC8848202.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCellsPHPublic Health
    20. Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine. JCO Precis Oncol. 2022 01; 6:e2000508. Charo LM, Eskander RN, Sicklick J, Kim KH, Lim HJ, Okamura R, Lee S, Subramanian R, Schwab R, Shatsky R, Plaxe S, Kato S, Kurzrock R. PMID: 35005995; PMCID: PMC8769125.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    21. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021 07 12; 39(7):989-998.e5. Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, Helsten TL, Forero-Torres A, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Asare SM, Wilson A, Singhrao R, Sit L, Hirst GL, Berry S, Sanil A, Asare AL, Matthews JB, Perlmutter J, Melisko M, Rugo HS, Schwab RB, Symmans WF, Yee D, Van't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ. PMID: 34143979; PMCID: PMC11064785.
      View in: PubMed   Mentions: 169     Fields:    Translation:HumansCTClinical Trials
    22. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 01 06; 19(1):77-102. Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Goggins M, Hutton ML, CGC, Karlan BY, Khan S, Klein C, Kohlmann W, CGC, Kurian AW, Laronga C, Litton JK, Mak JS, LCGC, Menendez CS, Merajver SD, Norquist BS, Offit K, Pederson HJ, Reiser G, CGC, Senter-Jamieson L, CGC, Shannon KM, Shatsky R, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Yurgelun MB, Darlow SD, Dwyer MA. PMID: 33406487.
      View in: PubMed   Mentions: 550     Fields:    Translation:Humans
    23. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nat Commun. 2020 10 02; 11(1):4965. Kato S, Kim KH, Lim HJ, Boichard A, Nikanjam M, Weihe E, Kuo DJ, Eskander RN, Goodman A, Galanina N, Fanta PT, Schwab RB, Shatsky R, Plaxe SC, Sharabi A, Stites E, Adashek JJ, Okamura R, Lee S, Lippman SM, Sicklick JK, Kurzrock R. PMID: 33009371; PMCID: PMC7532150.
      View in: PubMed   Mentions: 154     Fields:    Translation:Humans
    24. Management of Chimeric Antigen Receptor (CAR) T-Cell Toxicities: A Review and Guideline for Emergency Providers. J Emerg Med. 2020 Jul; 59(1):61-74. Gupta R, Roach C, Hryniewicki AT, Vilke GM, Shatsky RA, Coyne CJ. PMID: 32473867.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    25. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol. 2020 05 01; 6(5):676-684. Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Schwab R, Symmans WF, van 't Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Berry DA, Esserman LJ. PMID: 32053137; PMCID: PMC7058271.
      View in: PubMed   Mentions: 369     Fields:    Translation:HumansCTClinical Trials
    26. Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 08 01; 17(8):977-1007. Swarm RA, Paice JA, Anghelescu DL, Are M, Bruce JY, Buga S, Chwistek M, Cleeland C, Craig D, Gafford E, Greenlee H, Hansen E, Kamal AH, Kamdar MM, LeGrand S, Mackey S, McDowell MR, Moryl N, Nabell LM, Nesbit S, BCPS, O'Connor N, Rabow MW, Rickerson E, Shatsky R, Sindt J, Urba SG, Youngwerth JM, Hammond LJ, Gurski LA. PMID: 31390582.
      View in: PubMed   Mentions: 222     Fields:    Translation:Humans
    27. Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies. Mol Cancer Ther. 2019 05; 18(5):1001-1011. Shatsky R, Parker BA, Bui NQ, Helsten T, Schwab RB, Boles SG, Kurzrock R. PMID: 30926636.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    28. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians. J Emerg Med. 2018 10; 55(4):489-502. Hryniewicki AT, Wang C, Shatsky RA, Coyne CJ. PMID: 30120013.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    29. Application of the MASCC and CISNE Risk-Stratification Scores to Identify Low-Risk Febrile Neutropenic Patients in the Emergency Department. Ann Emerg Med. 2017 Jun; 69(6):755-764. Coyne CJ, Le V, Brennan JJ, Castillo EM, Shatsky RA, Ferran K, Brodine S, Vilke GM. PMID: 28041827.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    30. Afatinib in the treatment of breast cancer. Expert Opin Investig Drugs. 2014 Jul; 23(7):1039-47. Hurvitz SA, Shatsky R, Harbeck N. PMID: 24870559.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    31. Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer. Cancer Treat Rev. 2014 Mar; 40(2):320-6. Peddi PF, Shatsky RA, Hurvitz SA. PMID: 24011786.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    32. Multiplex PCR-ligation detection reaction assay for simultaneous detection of drug resistance and toxin genes from Staphylococcus aureus, Enterococcus faecalis, and Enterococcus faecium. J Clin Microbiol. 2010 Jan; 48(1):277-80. Granger K, Rundell MS, Pingle MR, Shatsky R, Larone DH, Golightly LM, Barany F, Spitzer ED. PMID: 19864481; PMCID: PMC2812281.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    33. Multiplexed identification of blood-borne bacterial pathogens by use of a novel 16S rRNA gene PCR-ligase detection reaction-capillary electrophoresis assay. J Clin Microbiol. 2007 Jun; 45(6):1927-35. Pingle MR, Granger K, Feinberg P, Shatsky R, Sterling B, Rundell M, Spitzer E, Larone D, Golightly L, Barany F. PMID: 17428930; PMCID: PMC1933048.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    Rebecca's Networks
    Concepts (131)
    Derived automatically from this person's publications.
    _
    Co-Authors (57)
    People in Profiles who have published with this person.
    _
    Similar People (59)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _